The combination of ICT01, a gamma 9 delta 2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial

S. Champiat,M. Wermke, C. Vicier,J. S. De Bono, C. Jungels,N. Vey, N. Kotecki, K. Wetzko, L. Ruhnke, E. Garralda, V. Galvao De Aguiar, P. Lorusso,A. De Gassart,E. Valentin, P. Brune, M. Iche, C. Leparquier, D. Olive, A. Marabelle, P. A. Frohna

Annals of Oncology（2022）

引用 0|浏览3

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要